Grant of Compulsory License for Bayer’s Nexavar in India raises more questions than answers

On March 12, 2012, the Patent Office of India, in its landmark ruling, granted its first ever Compulsory License (CL) for Bayer’s patented kidney and liver cancer drug Nexavar (Sorafenib), to the generic pharma player Natco, broadly citing the following … Continue reading

Encourage vaccine research and improve its access to demonstrate ‘prevention is better than cure’

Vaccines are one of the most successful and cost-effective public health interventions, which help preventing over 2 million deaths every year. The World Health Organization (WHO) defines vaccines as: “A vaccine is any preparation intended to produce immunity to a … Continue reading

Maintaining Supply Chain Security in pharmaceuticals: The need is now more than ever before.

In today’s globalized economy maintaining Supply Chain Security (SCS), especially in the pharmaceutical sector across the world, is more critical than ever before. We have many instances of SCS being seriously breached, not only in the emerging pharmaceutical markets but … Continue reading

Does China provide a more robust IPR environment than India?

Soon after the Product Patent Act was reintroduced in India effective January 1, 2005, a raging global debate commenced focusing on the robustness of the Indian Patent system. Quite often, many participants in the debate continue to compare the adequacies … Continue reading

Challenges for the Pharmaceutical Industry in the new paradigm – there are more questions than answers

To get insight into the future challenges of the pharmaceutical industry in general ‘Complete Medical Group’of U.K recently conducted a study with a sizeable number of senior participants from the pharmaceutical companies of various sizes and involving many countries. The … Continue reading

‘Prevention is better than cure’: Such a healthcare policy focus could effectively reduce the disease burden in India

First National Health Policy was passed by the Parliament of India in 1983 and was last updated in 2002. How much of the policy intent has seen the light of the day is anybody’s guess. Healthcare issues are not being … Continue reading

Ensuring ‘health outcomes’ based drugs prescriptions will be more beneficial for the patients in India than just ‘price control’ of drugs

Currently the global pharmaceutical market is undergoing a metamorphosis. The concept of ‘evidence-based medicine’ is gaining ground in the developed markets of the world, making the pharmaceutical companies generate requisite ‘health outcomes’ data using similar or equivalent products. Cost of … Continue reading

Are pharmaceuticals related more to chemicals than health?

I received a call from Professor Sam Gupta yesterday. (please refer to my article at: http://www.tapanray.in/profiles/blogs/the-professor-counterfeit) He is returning to the US next week. Before that, he felt, it will be nice if he and I can manage some time … Continue reading